Kartos Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• KRT-232 · Oncology
  Inhibits CDK4/6

Phase 1 pipeline

• AMG 232

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kartos Therapeutics, Inc. portfolio CI brief
• Kartos Therapeutics, Inc. pipeline updates RSS